Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;23(1):70-79.
doi: 10.1111/hiv.13165. Epub 2021 Sep 2.

Metabolic syndrome and body weight in people living with HIV infection: analysis of differences observed in three different cohort studies over a decade

Lucia Taramasso  1 , Paolo Bonfanti  2 , Elena Ricci  3 , Paolo Maggi  4 , Giancarlo Orofino  5 , Nicola Squillace  2 , Barbara Menzaghi  6 , Giordano Madeddu  7 , Chiara Molteni  8 , Francesca Vichi  9 , Erika Riguccini  10 , Annalisa Saracino  11 , Carmen Santoro  11 , Marta Guastavigna  5 , Daniela Francisci  10 , Antonio Di Biagio  12 , Giuseppe Vittorio De Socio  10 ; CISAI study group
Collaborators, Affiliations
Free article

Metabolic syndrome and body weight in people living with HIV infection: analysis of differences observed in three different cohort studies over a decade

Lucia Taramasso et al. HIV Med. 2022 Jan.
Free article

Abstract

Objectives: The aim of this study was to assess the incidence of being overweight and metabolic syndrome (MS) among people living with HIV (PHIV) in three different cross-sectional studies conducted over three different periods: 2005, 2011 and 2015.

Methods: This was a multi-centre, nationwide study. Data were collected in three studies from the CISAI group - SIMOne, HIV-HY and STOPSHIV - and included a total of 3014 PHIV. Logistic regression [odds ratio (OR), 95% confidence interval (CI)] was used to account for age and gender difference among three groups when comparing MS prevalence and being overweight; potential confounders were accounted for by including them in the regression equation.

Results: Overall, the mean age was 46.9 ± 10.2 years, and men comprised 73.3% of participants. Comparing 2005, 2011 and 2015, MS was present in 34.5%, 33.0% and 29.3% of PHIV, respectively. Adjusted OR for MS was 0.64 (95% CI: 0.52-0.78) in 2011 and 0.56 (95% CI: 0.46-0.69) in 2015 compared with 2005, while BMI (kg/m2 ) increased from 23.6 in 2005, 24.5 in 2011 and 24.5 in 2015, with a concomitant increase of being overweight from 29.4% to 39.5% to 39.6% (p < 0.0001).

Conclusions: In recent years, PHIV have had a significantly improved metabolic profile compared with previously, despite increasing weight and BMI.

Keywords: HIV; antiretroviral therapy; dyslipidaemia; metabolic syndrome; overweight; weight gain.

PubMed Disclaimer

References

REFERENCES

    1. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents., A Working Group of the Office of AIDS Research, Advisory Council (OARAC). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV [Internet]. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Ad.... Accessed July 25, 2021.
    1. European AIDS Clinical Society. EACS guidelines, version 10.1, October 2020 [Internet]. https://www.eacsociety.org/files/guidelines-10.1_finaljan2021_1.pdf. Accessed July 25, 2021.
    1. Taramasso L, Tatarelli P, Ricci E, et al. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA). BMC Infect Dis. 2018;18:357.
    1. Bagella P, Squillace N, Ricci E, et al. Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project. Infect Drug Resist. 2019;12:1385-1391.
    1. Orkin C, Squires KE, Molina J-M, et al. Doravirine/lamivudine/tenofovir disoproxil fumarate is non-inferior to efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus-1 infection: week 48 results of the DRIVE-AHEAD Trial. Clin Infect Dis. 2019;68:535-544.

Publication types

LinkOut - more resources